Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia

• Published in: Clinical lymphoma & myeloma Vol. 9; no. 1; pp. 56 - 58
• Main Authors: Ciccarelli, Bryan T., Yang, Guang, Hatjiharissi, Evdoxia, Ioakimidis, Leukothea, Patterson, Christopher J., Manning, Robert J., Xu, Lian, Liu, Xia, Tseng, Hsiuyi, Gong, Ping, Sun, Jenny, Zhou, Yangsheng, Treon, Steven P.
• Format: Journal Article
• Language: English
• Published: United States 01.03.2009
• Subjects: Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - blood; Bone marrow infiltration; ELISA; Enzyme-Linked Immunosorbent Assay; Humans; Hyperviscosity; Immunoglobulin M - blood; Middle Aged; Plasmapheresis; Rituximab; Serum IgM; Tumor necrosis factor family; Tumor Necrosis Factor Receptor Superfamily, Member 7 - blood; Waldenstrom Macroglobulinemia - blood; Waldenstrom Macroglobulinemia - drug therapy; Waldenström; Hyperviscosity; Tumor necrosis factor family; Bone marrow infiltration; Waldenström; Serum IgM; ELISA

The assessment of disease burden is often difficult in patients with Waldenström's macroglobulinemia (WM) who receive rituximab due to the induction of an IgM flare, and following the removal of serum IgM by plasmapheresis. Soluble CD27 (sCD27) is a tumor necrosis factor family member secreted...